Switch theme
Sign up to access all valuation multiples
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and Actemra for treating rheumatoid arthritis and covid patients.
1943
7.4K+
LTM Revenue $8.2B
LTM EBITDA $4.1B
$79.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chugai Pharmaceutical has a last 12-month revenue (LTM) of $8.2B and a last 12-month EBITDA of $4.1B.
In the most recent fiscal year, Chugai Pharmaceutical achieved revenue of $8.0B and an EBITDA of $3.7B.
Chugai Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chugai Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.2B | XXX | $8.0B | XXX | XXX | XXX |
| Gross Profit | $5.8B | XXX | $5.7B | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $4.1B | XXX | $3.7B | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 46% | XXX | XXX | XXX |
| EBIT | $3.9B | XXX | $3.7B | XXX | XXX | XXX |
| EBIT Margin | 47% | XXX | 46% | XXX | XXX | XXX |
| Net Profit | $2.8B | XXX | $2.7B | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Chugai Pharmaceutical's stock price is JPY 7583 (or $52).
Chugai Pharmaceutical has current market cap of JPY 12.48T (or $85.6B), and EV of JPY 11.53T (or $79.2B).
See Chugai Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $79.2B | $85.6B | XXX | XXX | XXX | XXX | $1.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Chugai Pharmaceutical has market cap of $85.6B and EV of $79.2B.
Chugai Pharmaceutical's trades at 9.9x EV/Revenue multiple, and 21.3x EV/EBITDA.
Equity research analysts estimate Chugai Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chugai Pharmaceutical has a P/E ratio of 30.8x.
See valuation multiples for Chugai Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $85.6B | XXX | $85.6B | XXX | XXX | XXX |
| EV (current) | $79.2B | XXX | $79.2B | XXX | XXX | XXX |
| EV/Revenue | 9.7x | XXX | 9.9x | XXX | XXX | XXX |
| EV/EBITDA | 19.5x | XXX | 21.3x | XXX | XXX | XXX |
| EV/EBIT | 20.5x | XXX | 21.3x | XXX | XXX | XXX |
| EV/Gross Profit | 13.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 30.8x | XXX | 32.2x | XXX | XXX | XXX |
| EV/FCF | 37.0x | XXX | 29.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChugai Pharmaceutical's last 12 month revenue growth is 4%
Chugai Pharmaceutical's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.3M for the same period.
Chugai Pharmaceutical's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chugai Pharmaceutical's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Chugai Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 46% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 44% | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chugai Pharmaceutical acquired XXX companies to date.
Last acquisition by Chugai Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Chugai Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Chugai Pharmaceutical founded? | Chugai Pharmaceutical was founded in 1943. |
| Where is Chugai Pharmaceutical headquartered? | Chugai Pharmaceutical is headquartered in Japan. |
| How many employees does Chugai Pharmaceutical have? | As of today, Chugai Pharmaceutical has 7.4K+ employees. |
| Who is the CEO of Chugai Pharmaceutical? | Chugai Pharmaceutical's CEO is Dr. Osamu Okuda. |
| Is Chugai Pharmaceutical publicy listed? | Yes, Chugai Pharmaceutical is a public company listed on TKS. |
| What is the stock symbol of Chugai Pharmaceutical? | Chugai Pharmaceutical trades under 4519 ticker. |
| When did Chugai Pharmaceutical go public? | Chugai Pharmaceutical went public in 1956. |
| Who are competitors of Chugai Pharmaceutical? | Similar companies to Chugai Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Chugai Pharmaceutical? | Chugai Pharmaceutical's current market cap is $85.6B |
| What is the current revenue of Chugai Pharmaceutical? | Chugai Pharmaceutical's last 12 months revenue is $8.2B. |
| What is the current revenue growth of Chugai Pharmaceutical? | Chugai Pharmaceutical revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Chugai Pharmaceutical? | Current revenue multiple of Chugai Pharmaceutical is 9.7x. |
| Is Chugai Pharmaceutical profitable? | Yes, Chugai Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Chugai Pharmaceutical? | Chugai Pharmaceutical's last 12 months EBITDA is $4.1B. |
| What is Chugai Pharmaceutical's EBITDA margin? | Chugai Pharmaceutical's last 12 months EBITDA margin is 50%. |
| What is the current EV/EBITDA multiple of Chugai Pharmaceutical? | Current EBITDA multiple of Chugai Pharmaceutical is 19.5x. |
| What is the current FCF of Chugai Pharmaceutical? | Chugai Pharmaceutical's last 12 months FCF is $2.1B. |
| What is Chugai Pharmaceutical's FCF margin? | Chugai Pharmaceutical's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Chugai Pharmaceutical? | Current FCF multiple of Chugai Pharmaceutical is 37.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
